Ouki surfaces proprietary drug repurposing intelligence across 22 disease conditions. Available to qualifying organisations under commercial agreement.
Over 4,000 medical research papers are published daily. No team can monitor the full breadth of published science across disease boundaries. Significant connections remain undiscovered.
FDA-approved drugs with established safety profiles can be repurposed for new indications — bypassing years of safety testing and dramatically compressing development timelines and costs.
Ouki operates continuously across 22 disease conditions, identifying mechanistically grounded drug repurposing hypotheses that cross-disciplinary research has not yet explored.
Each finding identifies a specific FDA-approved drug, the proposed mechanism in a new indication, and the precise gap in existing research. Available under commercial agreement.
Adalimumab + Etanercept
TNF-α identified as directly exciting pain nerves independently of inflammation — a mechanism never previously targeted in chronic pelvic pain.
May 11, 2026Minocycline + Standard DMT
Bidirectional amplification loop between microglia and T-cells identified as producing multiplicative neurodegeneration — and a way to break it.
May 11, 2026Daratumumab (Anti-CD38)
CD20-negative plasma cells identified as escaping rituximab and sustaining autoantibody production. Daratumumab addresses the precise mechanistic gap.
May 31, 2026Ouki generates research hypotheses, not medical advice. All findings require validation by qualified medical researchers through proper clinical studies. This platform is designed as a research acceleration tool for the scientific community.
Ouki's drug repurposing intelligence is available to qualifying pharmaceutical companies, biotech firms, and research institutions. All access is subject to NDA and commercial agreement.
Request Access →